Discover the benefits of Korsuva® (Difelikefalin) for chronic kidney disease

Hybio Pharmaceutical Co., Ltd. is proud to introduce Korsuva Difelikefalin, a revolutionary new product for the treatment of chronic pruritus in patients with chronic kidney disease (CKD-AUC), Korsuva Difelikefalin is a first-in-class kappa opioid receptor agonist that offers a novel approach to addressing the unmet medical needs of CKD-AUC patients. With its unique mechanism of action, Korsuva Difelikefalin has demonstrated promising efficacy and safety profiles in clinical trials, providing much-needed relief for patients suffering from this debilitating condition, At Hybio Pharmaceutical Co., Ltd., we are committed to advancing the field of renal medicine and improving the lives of CKD-AUC patients. With the introduction of Korsuva Difelikefalin, we are proud to offer a new treatment option that has the potential to make a meaningful impact on the quality of life for these patients, We are excited to bring Korsuva Difelikefalin to market and look forward to continuing our efforts to develop innovative solutions for the healthcare challenges of today and tomorrow